Research graph
References from Modeling the health and economic implications of adopting a 1-dose 9-valent human papillomavirus vaccination program in adolescents in low/middle-income countries: An analysis of Indonesia. Local targets link to admitted publications; unresolved targets remain external evidence.
Burden of human papillomavirus (HPV)-related cancers attributable to HPVs 6/11/16/18/31/33/45/52 and 58
10.1093/jncics/pky045 · 2019 · External reference
Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine
10.1086/597071 · 2009 · External reference
Recurrent respiratory papillomatosis: a state-of-the-art review
10.1016/j.rmed.2017.03.030 · 2017 · External reference
A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion
10.1086/516784 · 2007 · External reference
HPV vaccination in Southern Africa: A jab of hope in the fight against cervical cancer
10.1002/cncy.21738 · 2016 · External reference
HPV vaccine against anal HPV infection and anal intraepithelial neoplasia
10.1056/nejmoa1010971 · 2011 · External reference
Age-appropriate use of human papillomavirus vaccines in the U.S
10.1016/j.ygyno.2009.04.035 · 2009 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019
10.1016/j.ypmed.2020.106399 · 2021 · External reference
Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries
10.1016/s0140-6736(20)30068-4 · 2020 · External reference
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
10.3322/caac.21660 · 2021 · External reference
National implementation of HPV vaccination programs in low-resource countries: Lessons, challenges, and future prospects
10.1016/j.ypmed.2020.106335 · 2021 · External reference
Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women
10.1001/jama.2016.17615 · 2016 · External reference
Three-year follow-up of 2-dose versus 3-dose
2021 · External reference
9-valent human papillomavirus vaccine: A review of the clinical development program
10.1080/14760584.2017.1383158 · 2017 · External reference
Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study
10.1016/j.vaccine.2018.02.087 · 2018 · External reference
Evidence for single-dose protection by the bivalent HPV vaccine-Review of the Costa Rica HPV vaccine trial and future research studies
10.1016/j.vaccine.2017.12.078 · 2018 · External reference
Evaluation of durability of a single dose of the bivalent HPV vaccine: The CVT trial
10.1093/jnci/djaa011 · 2020 · External reference
Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs
10.1016/j.vaccine.2018.01.057 · 2018 · External reference
Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: A systematic review of evidence from clinical trials
10.1016/j.vaccine.2019.12.017 · 2020 · External reference
Unresolved reference
External reference
Human papillomavirus vaccine effectiveness against incident genital warts among female health-plan enrollees, United States
10.1093/aje/kwx253 · 2018 · External reference
A single dose of quadrivalent human papillomavirus (HPV) vaccine is immunogenic and reduces HPV detection rates in young women in Mongolia, six years after vaccination
10.1016/j.vaccine.2020.04.041 · 2020 · External reference
Effectiveness of 1, 2, and 3 doses of human papillomavirus vaccine against high-grade cervical lesions positive for human papillomavirus 16 or 18
10.1093/aje/kwz253 · 2020 · External reference
Prevalence of human papillomavirus infection by number of vaccine doses among US women
10.1001/jamanetworkopen.2019.18571 · 2019 · External reference
Human papillomavirus vaccine effectiveness against HPV infection: Evaluation of one, two, and three doses
10.1093/infdis/jiz555 · 2020 · External reference
Comparison of the long-term impact and clinical outcomes of fewer doses and standard doses of human papillomavirus vaccine in the United States: A database study
10.1002/cncr.32700 · 2020 · External reference
Cervical intraepithelial neoplasia rates in British Columbia women: A population-level data linkage evaluation of the school-based HPV immunization program
10.1093/infdis/jiz422 · 2020 · External reference
P832 Effectiveness of the quadrivalent HPV vaccine against HSIL and CIN: a data-linkage study
2019 · External reference
Single-dose HPV vaccination efficacy among adolescent girls and young women in Kenya (the KEN SHE Study): study protocol for a randomized controlled trial
10.1186/s13063-021-05608-8 · 2021 · External reference
Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results
10.1038/s41591-023-02658-0 · 2023 · External reference
Comparing one dose of HPV vaccine in girls aged 9–14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial
10.1016/s2214-109x(22)00306-0 · 2022 · External reference
Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial
10.1016/s2214-109x(22)00309-6 · 2022 · External reference
HPV16/18 Antibody Responses After a Single Dose of Nonavalent HPV Vaccine
10.1542/peds.2022-060301 · 2023 · External reference
Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study
10.1016/s1470-2045(21)00453-8 · 2021 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country
10.1016/j.vaccine.2018.04.061 · 2018 · External reference
Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis
2021 · External reference
Global impact and cost-effectiveness of one-dose versus two-dose human papillomavirus vaccination schedules: a comparative modelling analysis
10.1186/s12916-023-02988-3 · 2023 · External reference
Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review
10.1016/j.vaccine.2013.06.060 · 2013 · External reference
Unresolved reference
External reference
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials
10.1016/s1470-2045(15)00047-9 · 2015 · External reference
Model-estimated effectiveness of single dose 9-valent HPV vaccination for HIV-positive and HIV-negative females in South Africa
10.1016/j.vaccine.2018.02.023 · 2018 · External reference
Now or later: Health impacts of delaying single-dose HPV vaccine implementation in a high-burden setting
2022 · External reference
Evidence-based impact projections of single-dose human papillomavirus vaccination in India: a modelling study
10.1016/s1470-2045(22)00543-5 · 2022 · External reference
Modeling the health and economic implications of adopting a 1-dose 9-valent human papillomavirus vaccination regimen in a high-income country setting: An analysis in the United Kingdom
10.1016/j.vaccine.2022.02.067 · 2022 · External reference
Unresolved reference
External reference
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women
10.1056/nejmoa1405044 · 2015 · External reference
Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials
10.1016/s0140-6736(07)60852-6 · 2007 · External reference
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
10.1056/nejmoa061760 · 2007 · External reference
Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males
10.1056/nejmoa0909537 · 2011 · External reference
Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials
10.1016/s0140-6736(07)60777-6 · 2007 · External reference
Model for assessing human papillomavirus vaccination strategies
10.3201/eid1301.060438 · 2007 · External reference
Impact of vaccinating boys and men against HPV in the United States
10.1016/j.vaccine.2010.08.030 · 2010 · External reference
Public health impact and cost-effectiveness of catch-up 9-valent HPV vaccination of individuals through age 45 years in the United States
2021 · External reference
Unresolved reference
External reference
Assessing the Health and Economic Outcomes of a 9-Valent HPV Vaccination Program in the United Kingdom
10.36469/jheor.2022.34721 · 2022 · External reference
Cervical cancer prevention in Indonesia: An updated clinical impact, cost-effectiveness and budget impact analysis
10.1371/journal.pone.0230359 · 2020 · External reference
Unresolved reference
External reference
Using observational data to explore the hypothesis that a single dose of current HPV vaccines can provide durable protection
2022 · External reference
Unresolved reference
External reference
Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study
10.1016/s0140-6736(10)62342-2 · 2011 · External reference
Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities
10.1371/journal.pmed.0050132 · 2008 · External reference
Cervical cancer screening in low-and middle-income countries: A systematic review of economic evaluation studies
2022 · External reference
Barriers to cervical cancer screening in Africa: a systematic review
10.1186/s12889-024-17842-1 · 2024 · External reference
National vaccination coverage among adolescents aged 13–17 years—national immunization survey-teen, United States, 2021
10.15585/mmwr.mm7135a1 · 2022 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
